Ascendis Pharma A (ASND) Research & Development (2014 - 2026)
Ascendis Pharma A (ASND) reported Research & Development of -$69.1 million for Q1 2026, up 24.12% on a YoY basis from -$55.7 million in Q1 2025, and up 24.01% sequentially from -$91.0 million in Q4 2025.
Ascendis Pharma A (ASND) Research & Development (2014 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 13 years of Research & Development data on file, last reported at -$69.1 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 24.12% year-over-year to -$69.1 million; the trailing twelve-month figure through Mar 2026 stood at -$156.8 million (up 5.94% YoY), and the FY2025 full-year result was $353.4 million, up 6.36% from the prior year.
- Research & Development rose to -$69.1 million in Q1 2026, from -$91.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $121.3 million in Q3 2023 to a low of -$91.1 million in Q1 2025.
- A 5-year average of $35.3 million and a median of $89.9 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 47.55% in 2022 and tumbled 218.63% in 2025, its largest moves.
- Tracing ASND's Research & Development over 5 years: stood at $110.8 million in 2022, then decreased by 11.76% to $97.8 million in 2023, then slumped by 186.65% to -$84.7 million in 2024, then fell by 7.36% to -$91.0 million in 2025, then climbed by 24.01% to -$69.1 million in 2026.
- Business Quant data shows ASND's Research & Development at -$69.1 million in Q1 2026, -$91.0 million in Q4 2025, and -$78.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Ascendis Pharma A | 15.35 Bn | 14.68 Bn | 268.20 Mn | -69.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.13 Mn |
| Dec 31, 2025 | -90.97 Mn |
| Sep 30, 2025 | -78.19 Mn |
| Jun 30, 2025 | 81.49 Mn |
| Mar 31, 2025 | -91.10 Mn |
| Dec 31, 2024 | -84.73 Mn |
| Sep 30, 2024 | -80.77 Mn |
| Jun 30, 2024 | 89.90 Mn |
| Mar 31, 2024 | 76.79 Mn |
| Dec 31, 2023 | 97.78 Mn |
| Sep 30, 2023 | 121.31 Mn |
| Jun 30, 2023 | 114.36 Mn |
| Mar 31, 2023 | 113.90 Mn |
| Dec 31, 2022 | 110.82 Mn |
| Sep 30, 2022 | 98.24 Mn |
| Jun 30, 2022 | 96.44 Mn |
| Mar 31, 2022 | 93.37 Mn |
| Dec 31, 2021 | 75.10 Mn |
| Sep 30, 2021 | 69.30 Mn |
| Jun 30, 2021 | 100.32 Mn |